All Industry News articles
-
NewsAFYREN strengthens its Executive Committee with appointment of Laurent Pou as Industrial Director
AFYREN, a greentech company offering manufacturers biobased, low-carbon ingredients through a unique fermentation technology based on a circular model, has announced the appointment of Laurent Pou as Industrial Director.
-
NewsPhage therapy at a crossroads: global experts gather for ground-breaking 2025 Congress
Global multidisciplinary experts and innovators convene for the 8th World Congress on Targeting Phage Therapy 2025 on June 10-11. This leading event is dedicated to the advancement of bacteriophage science and applications in multiple bioscience areas.
-
NewsUpdated guidelines for pediatric Mycoplasma pneumoniae infection
In light of the rise in antibiotic resistance, new guidelines are released with detailed recommendations of diagnosis and treatment strategies for pediatric Mycoplasma pneumoniae pneumonia (MPP), along with the means to manage severe complications.
-
NewsTecovirimat is safe but ineffective as treatment for clade II mpox
The antiviral drug tecovrimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox lesions or improve pain control among adults in an international clinical trial.
-
NewsDrug may prevent COVID-19 in exposed people within households, major trial finds
An international clinical trial of the oral antiviral drug, ensitrelvir, which has been proved to prevent COVID-19 cases, was conducted and found to be very effective. The drug will be awaiting for approval before becoming widely available.
-
NewsFA Bio licenses two microbes to IFF’s Crop Biologicals division to advance microbial solutions for crop health
FA Bio, a leader in the discovery of sustainable agricultural products, has extended a license agreement on two microbials to IFF’s Crop Biologicals business.
-
NewsScottish biotech company Lentitek secures £1m funding to advance next generation cancer treatments
Biotech company Lentitek Ltd has secured £700,000 in private funding from Equity Gap, bringing its total investment to £1 million in the last six months. It develops manufacturing technologies for lentiviral vectors, used with CAR-T cell and gene therapies.
-
NewsCentauri Therapeutics selects first clinical candidate for immunotherapeutic treatment of Gram-negative bacterial infections
Centauri Therapeutics Limited has announced the selection of its first clinical candidate in the ABX-01 programme. The compound is designed to target serious Gram-negative bacterial infections in the lung.
-
NewsNewly launched Enodia Therapeutics is a biotech company with a new approach for targeted protein degradation
Argobio and the Institut Pasteur have announced the launch of Enodia Therapeutics, a groundbreaking French biotech company dedicated to block and degrade disease-causing proteins for treating cancer, inflammatory diseases and viral infections.
-
NewsStudy reveals how bacteria in microbiome medicine trigger tumor-killing cells
Microbiotica has presented new data on the mechanism of action of MB097, a clinical-stage drug candidate being developed as a co-therapy in combination with KEYTRUDA® (pembrolizumab) in patients with advanced melanoma.
-
NewsBeacon Technology Solutions, Illinois Tech awarded grant to advance far-UVC disinfection research
Beacon Technology Solutions, with collaborators at Illinois Institute of Technology, has been awarded a grant to support a novel study on how Far-UVC technology can help mitigate the spread of infectious diseases in public spaces.
-
NewsScottish bio-tech company secures £3.4m investment
Scottish biotech engineering company uFraction8 has secured £3.4m in new investment following the completion of a funding round led by Foresight Group.
-
NewsLancaster University spinout secures funding to advance healthcare diagnostics
Lancaster University spin out CCI Photonics has secured significant funding to develop its diagnostic technology, which aims to improve healthcare outcomes by using AI to detect infectious diseases and determine patients’ antibiotic susceptibilities in under 15 minutes.
-
NewsRising threat of carbapenem-resistant Enterobacteriales (CRE) spurs urgent healthcare alert
The deteriorating epidemiological situation of carbapenem-resistant Enterobacteriales (CRE) has spurred ECDC to alert EU/EAA countries to the importance of controlling the spread of CRE infections to safeguard their healthcare systems.
-
NewsGlobal research on hydrothermal pretreatment: A green leap for biorefineries
From a global analysis of the research in hydrothermal pretreatment, a bibliometric study highlights its use as the future of biorefineries for sustainable biomass conversion.
-
NewsValneva reports high sustained immune response in adolescents one year after Chikungunya Vaccine
Valneva SE, a specialty vaccine company, has reported further positive Phase 3 data in adolescents for its single-shot chikungunya virus (CHIKV) vaccine, IXCHIQ®, which showed a sustained 98.3% sero-response rate one-year after single vaccination.
-
NewsCARB-X funds Melio to develop rapid diagnostic to detect neonatal sepsis
CARB-X will award biotechnology company Melio US$3.5M to develop and execute a technical feasibility workplan for its culture-free platform designed to identify blood stream infections including neonatal sepsis.
-
NewsCARB-X funds Peptilogics to develop a novel, broad-spectrum therapeutic to treat fracture-related infections
CARB-X will award Peptilogics US$3.3 million to develop and execute a workplan for its slow-release formulation of a novel, broad-spectrum therapeutic, zaloganan-CR, an engineered peptide intended for use in preventing infection after high-energy-traumatic bone injuries.
-
NewsStart-up EBViously announces its launch
EBViously, a spin-off of Helmholtz Munich, officially started operations on 11 November 2024. The company is developing a preventive vaccine against diseases caused by the Epstein-Barr virus (EBV).
-
NewsBreakthrough infection test designed to tackle AMR on target for 2025 UK NHS availability after positive trial results
UK medtech company Presymptom Health has announced positive results from its clinical trial of diagnostic technology in the management of infection and sepsis in patients presenting to Emergency Departments with respiratory infection.